The Oncology Institute, Inc. (TOI)
NASDAQ: TOI · Real-Time Price · USD
2.880
+0.170 (6.27%)
Apr 23, 2025, 4:00 PM EDT - Market closed

Company Description

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States.

The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other.

It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance services.

The company also provides and manages clinical trials, palliative care programs, stem cell transplants services, other care delivery models associated with non-community-based academic, and tertiary care settings; and conducts clinical trials for a range of pharmaceutical, and medical device companies.

It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

The Oncology Institute, Inc.
The Oncology Institute logo
Country United States
Founded 2007
Industry Medical Care Facilities
Sector Healthcare
Employees 825
CEO Daniel Virnich

Contact Details

Address:
18000 Studebaker Road, Suite 800
Cerritos, California 90703
United States
Phone 562 735 3226
Website theoncologyinstitute.com

Stock Details

Ticker Symbol TOI
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001799191
CUSIP Number 68236X100
ISIN Number US68236X1000
Employer ID 84-3562323
SIC Code 8011

Key Executives

Name Position
Dr. Daniel Virnich FACHE, M.B.A., M.D. Chief Executive Officer and Executive Director
Richard Alan Barasch Chairman of the Board
Jeremy N. Castle M.B.A. Chief Operations Officer
Dr. Yale D. Podnos F.A.C.S., M.D., M.P.H. Chief Medical Officer
Robert Carter Chief Financial Officer
Austin Lee Vice President of Accounting and Controller
Mark Hueppelsheuser Esq. General Counsel
Jordan McInerney Chief Development Officer
Stephen Cella Senior Vice President of Finance

Latest SEC Filings

Date Type Title
Apr 11, 2025 8-K Current Report
Apr 8, 2025 D Notice of Exempt Offering of Securities
Mar 28, 2025 SCHEDULE 13D/A Filing
Mar 27, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 27, 2025 8-K Current Report
Mar 27, 2025 DEF 14A Other definitive proxy statements
Mar 26, 2025 ARS Filing
Mar 26, 2025 10-K Annual Report
Mar 25, 2025 8-K Current Report
Mar 24, 2025 8-K Current Report